Role of artificial intelligence applied to ultrasound in gynecology oncology: A systematic review
Francesca Moro,Marianna Ciancia,Drieda Zace,Marica Vagni,Huong Elena Tran,Maria Teresa Giudice,Sofia Gambigliani Zoccoli,Floriana Mascilini,Francesca Ciccarone,Luca Boldrini,Francesco D'Antonio,Giovanni Scambia,Antonia Carla Testa
DOI: https://doi.org/10.1002/ijc.35092
2024-07-13
International Journal of Cancer
Abstract:What's new? Artificial intelligence is increasingly used in advanced medicine and is now being applied to ultrasound imaging in gynecological oncology. However, a deeper understanding of the capabilities and limitations of AI would help improve the management of cancer patients from diagnosis to treatment. The current evidence analyzed in this systematic review of 50 studies supports the role of AI as a complementary research and clinical tool in diagnosis, patient stratification, and prediction of histopathological correlation in gynecological malignancies. AI applications are however still largely lacking for pathologies other than ovarian cancer. The aim of this paper was to explore the role of artificial intelligence (AI) applied to ultrasound imaging in gynecology oncology. Web of Science, PubMed, and Scopus databases were searched. All studies were imported to RAYYAN QCRI software. The overall quality of the included studies was assessed using QUADAS‐AI tool. Fifty studies were included, of these 37/50 (74.0%) on ovarian masses or ovarian cancer, 5/50 (10.0%) on endometrial cancer, 5/50 (10.0%) on cervical cancer, and 3/50 (6.0%) on other malignancies. Most studies were at high risk of bias for subject selection (i.e., sample size, source, or scanner model were not specified; data were not derived from open‐source datasets; imaging preprocessing was not performed) and index test (AI models was not externally validated) and at low risk of bias for reference standard (i.e., the reference standard correctly classified the target condition) and workflow (i.e., the time between index test and reference standard was reasonable). Most studies presented machine learning models (33/50, 66.0%) for the diagnosis and histopathological correlation of ovarian masses, while others focused on automatic segmentation, reproducibility of radiomics features, improvement of image quality, prediction of therapy resistance, progression‐free survival, and genetic mutation. The current evidence supports the role of AI as a complementary clinical and research tool in diagnosis, patient stratification, and prediction of histopathological correlation in gynecological malignancies. For example, the high performance of AI models to discriminate between benign and malignant ovarian masses or to predict their specific histology can improve the diagnostic accuracy of imaging methods.
oncology